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Introduction: Allergic rhinitis is a Type 1 mediated hypersensitivity reaction 
which is characterized by one or more of the following symptoms which is sneezing, 
rhinorrhea, nasal congestion and nasal itchiness. Management of allergic rhinitis 
includes patient education and counseling, pharmacotherapy, and allergen-specific 
immunotherapy. In this study, we were determining the role of channa straitus as a 
adjuvant therapy in treatment of allergic rhinitis      
 
Objectives: To detemine the therapeutic efect of channa striatus and to compare 
the total nasal symptom score and levels of IgE between channa straitus and placebo 
group. 
 ii 
Methodology: There were 70 patients aged 18 to 50 years old, diagnosed 
allergic rhinitis based on total symptoms score, nasoendoscopy findings, and positive 
skin prick test were involved in this prospective, randomized, double blinded, 
comparative clinical trial. They were divided equally into 2 groups which is channa and 
placebo group. The patients were screened with detailed history, physical examination 
and nasoendosopy.Baseline FBC, BUSE, LFT, and IgE levels were obtained prior to 
commencement of treatment. Both groups were treated with the same conventional 
treatment, antihistamine (levocetrizine 5mg) with local corticosteroid nasal spray 
(Avamys nasal spray). Assessment of compliance, drug diary, adverse effects, symptoms 
score and nasendoscopy were made at Week 0, 2th, and 6th.. Serum IgE levels were 
measured at week 0 and 6th. 
 
Results: Channa group showed significant improvement in nasal symptoms 
such as nasal blockage (p=0.034) and nasal itchiness (p=0.022), non-nasal symptoms 
such as eye itchiness (p=0.032) and symptoms in general (p=0.026). IgE levels were 
significantly lower in Channa group compared to placebo (p-value <0.001).There were 
no statistical significant in term of nasal discharge, sneezing, palate itchiness, and smell 
score. There were no serious adverse reactions reported in the channa group. 
 
Conclusions: Channa striatus has a beneficial role in improving nasal and non-
nasal symptoms with reduction in IgE levels in patients suffering from allergic rhinitis. 
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PREFACE 
 
 
Allergic rhinitis is a chronic allergic inflammation of the nasal airways. Its occurs when 
an allergen, such as dust, pollen, is inhaled by individual with a sensitized immune 
system. It is an IgE mediated inflammatory reaction presenting with nasal obstruction, 
watery nasal discharge, sneezing, itchy nose and eyes. All these symptoms would 
significantly have a physical, physiological, and social impact to the patients. . The 
objective of this study was to determine the effects of Channa Striatus as an adjuvant 
and its therapeutic effect in the management of allergic rhinitis. We hope that this study 
can be made as a benchmark to further explore the role of Channa Striatus as a adjunct 
in treatment of Allergic Rhinitis and further improve patients quality of life  
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ABSTRAK 
 
 
 
Tajuk  
Kerberkesanan Channa Striatus sebagai terapi tambahan dalam rawatan alahan 
radang hidung.  
 
Pengenalan  
Alahan radang hidung adalah penyakit jenis 1 tindak balas hipersensitif serta merta, 
yang dicirikan oleh satu atau lebih daripada gejala berikut seperti bersin, hidung 
berair,hidung tersumbat dan hidung gatal. Pengurusan alahan radang hidung tewrmasuk 
pendidikan dan kaunselling pesakit, farmakoterapi, dan imunoterapi alergen tertentu.  
 
Objektif 
Untuk menentukan kesan terapeutik channa striatus dan membandingkan keseleruhan 
skor gejala hidung dan paras IgE dengan kumpulan channa striatus dan placebo. 
 
Metodologi 
Seramai 70 pesakit alahan radang hidung yang berumur 18 hingga 50 tahun telah 
mengambil bahagian dalam kajian prospektif ini. Kesemua pesakit ini telah dibahagikan 
secara rawak kepada dua kumpulan dalam kuantiti yang sama iaitu kumpulan channa 
dan placebo. Sejarah pesakit, pemeriksaan fizikal and endoskopi hidung disaring 
terlebih dahulu. Paras FBC, BUSE, LFT dan IgE telah diambil sebelum memulakan 
rawatan. Kedua-dua kumpulan diberikan rawatan yang konvesional iaitu antihistamin 
 xiii 
(levocetrizine 5mg) with spray hidung corticosteroid setempat (Avamys nasal spray).  
Pemenuhan ubat, diari ubat, kesan sampingan, skor gejala, dan endoskopi hidung  
dinilai pada minggu 0, ke-2, dan ke-6. Paras serum IgE diambil pada minggu 0 dan ke-6. 
 
Keputusan 
Kumpulan channa menunjukan pengurangan yang signifikan bagi gejala hidung seperti 
hidung tersumbat (p=0.034) dan hidung gatal (p=0.022), gejala bukan dari hidung 
seperti kegatalan mata (p=0.032) and gejala keseleruhan (p=0.026). Paras IgE 
menunjukan pengurangan yang signifikan dalam kumpulan Channa berbanding dengan 
kumpulan placebo (p-value <0.001). Tiada perbezaan yang signifikan dalam skor gejala 
hidung berair, bersin, mulut gatal, and pembauan. Tiada kesan sampingan yang 
dilaporkan dalam kumpulan  channa. 
 
 
Kesimpulan 
Channa striatus memainkan peranan yang baik sebagai terapi tambahan dalam 
mengurangkan gejala hidung dan bukan hidung disamping mengurangkan paras IgE 
bagi pesakit alahan radang hidung. 
 
Kata-kata penting: Alahan radang hidung, Channa Striatus, IgE  
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ABSTRACT 
 
Title 
The Effects of Channa Striatus as an Adjuvant Therapy in Treatment of Allergic 
Rhinitis  
 
Introduction 
Allergic rhinitis is a Type 1 mediated hypersensitivity reaction which is characterized 
by one or more of the following symptoms which is sneezing, rhinorrhea, nasal 
congestion and nasal itchiness. Management of allergic rhinitis includes patient 
education and counseling, pharmacotherapy, and allergen-specific immunotherapy. In 
this study, we were determining the role of channa straitus as a adjuvant therapy in 
treatment of allergic rhinitis      
 
Objectives 
To detemine the therapeutic efect of channa striatus and to compare the total nasal 
symptom score and levels of IgE between channa straitus and placebo group. 
 
Methodology 
There were 70 patients aged 18 to 50 years old, diagnosed allergic rhinitis based on total 
symptoms score, nasoendoscopy findings, and positive skin prick test were involved in 
this prospective, randomized, double blinded, comparative clinical trial. They were 
 xv 
divided equally into 2 groups which is channa and placebo group. The patients were 
screened with detailed history, physical examination and nasoendosopy. 
Baseline FBC, BUSE, LFT, and IgE levels were obtained prior to commencement of 
treatment. Both groups were treated with the same conventional treatment, 
antihistamine (levocetrizine 5mg) with local corticosteroid nasal spray (Avamys nasal 
spray).  Assessment of compliance, drug diary, adverse effects, symptoms score and 
nasendoscopy were made at Week 0, 2th, and 6th.. Serum IgE levels were measured at 
week 0 and 6th. 
 
Results 
Channa group showed significant improvement in nasal symptoms such as nasal 
blockage (p=0.034) and nasal itchiness (p=0.022), non-nasal symptoms such as eye 
itchiness (p=0.032) and symptoms in general (p=0.026). IgE levels were significantly 
lower in Channa group compared to placebo (p-value <0.001).There were no statistical 
significant in term of nasal discharge, sneezing, palate itchiness, and smell score. There 
were no serious adverse reactions reported in the channa group. 
 
Conclusions 
Channa striatus has a beneficial role in improving nasal and non-nasal symptoms with 
reduction in IgE levels in patients suffering from allergic rhinitis. 
 
Key words: Allergic rhinitis, Channa Striatus, IgE  
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CHAPTER 1 
INTRODUCTION 
 
1.1 Epidemiology 
 
Allergic rhinitis is an inflammation of the nasal mucous membrane, an IgE mediated 
reaction, presenting with nasal obstruction, watery nasal discharge, sneezing and itchy nose 
and eyes (Howarth, 1997). Allergic rhinitis is still one of the most widespread chronic 
inflammatory diseases in the world. It represents a global health issue affecting between 10% 
to 25% of the world population with increasing prevalence over the last decade (Strachan et 
al., 1997). It is the most common chronic condition in children and it is estimated to affect up 
to 40% of all children (Benedikt LM. et al, 2006). There is a wide variation among Asian 
countries. The prevalence of asthma in Japan had increased from 3.5% in 1982 to 4.6% in 
1999 to 9.1% in 2006 and it was accompanied by an increase in allergic rhinitis of up to 32% 
(Arbes et al., 2009). Similarly,2 surveys performed in Taiwan using an identical method 
showed that the prevalence of childhood asthma had increased from 1.3% in 1974 to 5.07% 
in 1985 (Holm et al,1995). The percentage of children in Singapore who had experienced 
asthma at least once increased from 5.5% in 1967 to 13.7% in 1987 and to 20.7% in 1996.In 
Singaporean pre-schoolers aged 4 to 6 years, the cumulative and previous 12-month 
prevalence of wheezing were 27.5% and 16.0% respectively. Asthma was reported by 11.7% 
of this group of children, and the current prevalence of rhinitis was 25.3%. 
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Although allergic rhinitis occurs frequently which affects both adults and children, 
however it remains largely undiagnosed. The condition maybe frequently trivialized (by the 
patient) and/or unrecognized (by the doctor), resulting in inadequate control of symptoms 
(Sibbald, 1991). In the United Kingdom, only 18% of subjects with rhinitis had visited their 
general practitioner over the preceding 2 years concerning their allergic rhinitis (James, 
2002). A later study in France showed that 19% of 230 patients with typical symptoms of 
allergic rhinitis had never consulted a doctor for their nasal problem (Horak et al., 2002). 
However, allergic rhinitis has been identified as one of the top ten reasons for visits to 
primary care clinic (Enerback et al., 1986). 
 
1.2   Mortality & Morbidity 
 
Although the prevalence of allergic rhinitis is increasing worldwide and considered as 
a major health problem, it is not associated with mortality unless if accompanied by severe 
asthma or anaphylaxis. However it carries a significant morbidity. Morbidity is manifested in 
several ways. Annually, an estimated 824,000 school days are missed, and an estimated 
4,230,00 days of reduced quality of life functions are reported (Mariana et al.,2000). Allergic 
rhinitis often coexist with other disorders, such as asthma and maybe associated with asthma 
exacerbations (McMenamin 1994, Mariana 1996, Mediaty, A., NeuberK.2005).These co-
exist morbidities suggesting the concept of “one airway, one disease” (Gordon et al ., 1997). 
Evidence now suggests that uncontrolled allergic rhinitis can actually worsen the                                                            
inflammation associated with asthma (Valero et al., 2007). This could lead to further 
morbidity and even mortality.  
3 
 
Patients with asthma and allergic rhinitis have a reduced quality of life, and the 
burden of asthma, as assessed by disability adjusted life years, ranks 22nd among all diseases 
worldwide (Allergic rhinitis and its Impact on Asthma (ARIA) 2008). Allergic rhinitis is also 
associated with otitis media, Eustachian tube dysfunction, sinusitis, nasal polyps, allergic 
conjunctivitis, and atopic dermatitis ( Knani et al., 1992). Individuals with allergic rhinitis 
have a higher frequency of these conditions than individuals without allergic rhinitis. Allergic 
rhinitis can frequently lead to insignificant impairment of quality of life. Symptoms such as 
fatigue, drowsiness (due to the disease or other medications) and malaise can lead to impaired 
work and school performance, learning difficulties, missed school or work days, sleep 
disorders and traffic accidents (Leurs et al.,2002,Leynaert et al.,2000). It can affect the 
physical, physiological and social aspects of the patients life and also can impact their 
functions at work. These aspects or “quality of life” issues provide information that cannot be 
obtained using conventional clinical and functional measures and they provide a focus on 
patient’s own perception of disease. Recent studies suggest that allergic rhinitis adversely 
affects sleep related quality of living of  patients (Jonathan C,2000). The sleep related quality 
of life impairment in patients with AR is however assessed by means of questionnaires (Pratt 
E.L, et al., 2007). The annual costs of treating asthma and allergic rhinitis and associated 
diseases, both direct costs (hospitalization, medications) and indirect costs (time lost from 
work, premature death) are substantial and represent an even heavier burden in societies with 
emerging economies. The Asthma Insights and Reality in Asia-Pacific region showed that the 
annual per-patient direct costs ranged from US $108 in Malaysia to US $ 1010 in Hong Kong 
(Zamzil et al., 2010). The overall costs (direct and indirect) of allergic rhinitis were recently 
estimated to be ranging from $5.3 to $20  
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billion per year (Togias, 2000). These include the costs associated with medications, lost 
work productivity, and physician consultations. Approximately US $3 billion are spent 
annually in Germany alone (Novak, 2003). Employees with untreated allergies are reportedly 
10% less productive than coworkers without allergies, whereas those using allergy 
medications to treat allergic rhinitis were only 3% less productive (Laslet M.V, et al, 2000). 
This suggest that effective medications may reduce the overall cost of decreased productivity. 
As a consequence, its impact on quality of life, the association with multiple co-morbidities 
and the considerable socio-economic burden, allergic rhinitis is considered a major 
respiratory disorder (Van Cauwenberge, 2000, Van Hoecke, 2006). 
 
1.3   Pathophysiology 
 
Allergic rhinitis involves inflammation of the mucous membranes of the nose, eyes, 
Eustachian tubes, middle ear, sinuses and pharynx. The nose is undoubtly involved while the 
other organs are affected only in certain individuals. The inflammation of mucous 
membranes is characterized by a complex interaction of inflammatory mediators but 
ultimately is triggered by an immunoglobulin E (IgE)-mediated response to an extrinsic 
protein or polysaccharides which is called allergen. Allergy represents an exaggerated 
immunologic response to an otherwise innocuous agent, which causes harm to the host.  
Allergic rhinitis is clinically defined as a symptomatic disorder of nose, which occurs 
following exposure to allergen that causes IgE- mediated inflammation of nasal mucosa. The 
cardinal symptoms of allergic rhinitis as mentioned above and characteristically one or more  
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of above symptoms should be present ( Allergic Rhinitis and Its Impact on Asthma (ARIA) 
2008 update).The process by which symptoms of allergic rhinitis is produced is complex, 
involving cells, mediators, cytokines and adhesion molecules and it can be divided into           
4 steps: 
1. Sensitization 
2. Early phase reaction 
3. Late phase reaction 
4. Systemic activation 
  1.3.1 Sensitization 
Allergens in the environment such as house dust mite, pollen act as the first step in this 
process. They may be harmless to the non-atopic individuals but in atopics, they might trigger 
cascades of events. These allergens will adhere to antigen presenting cells in the nose, are the 
dendritic cells called Langerhans cells which is a CDI-positive cells containing Birbeck 
granules. These cells are increased after allergen challenge in allergic rhinitis patients. The 
Langerhans cells will form a network in human respiratory mucosa at its largest amount in 
the epithelial surface of upper airways. The dendritic cells will present the allergen to the T 
lymphocytes in the local lymph nodes (Varga et al., 1999) 
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Antigen presentation by dendritic cells needs T cell receptor recognition of peptide 
fragment associated with Major Histocompatibility Complex (MHC) molecule and co-
stimulatory for example CD 28 and B7 or CD40 and CD40 ligand. Resting Langerhans cells 
are well equipped for antigen binding and processing. However, in order for the dendritic 
cells to stimulate T cells effectively, they need maturation signal for instance viruses, or 
adjuvant such as diesel exhaust particles. Without these signal, Tcells response will not 
happen. Airway mucosal dendritic cells play an important part in determining primary 
sensitization or tolerance to antigens. In atopic individuals, the two cells predominates at the 
site of allergic response. There is some evidence said that antigen presentation airway 
dendritic cells (Langerhans cells) leads to the preferential development of a Th2 response. In 
secondary immune response, any cells expressing surface MHC class 2 may serve as an 
antigen presenting cell, include the activated nasal epithelium. 
Antigen presentation by dendritic cells will lead to Th2 response, and Th2 cells will 
secrete cytokines, mainly IL-4,IL-3 and IL-5. They also stimulate B lymphocytes to 
proliferate, migrate to nasal lining and produce antibody of immunoglobulin E (IgE) class.B 
cells are found in epithelium and lamina propria of nasal mucosa, comprising approximately 
20 percent of the total lymphocyte population in perennial allergic rhinitis patients (Weiner at 
al., 1998). 
Once IgE is produced, they will adhere to FcER1 of the mast cells, and this mast cell 
complex will respond to subsequent allergen exposure. The patient is thus sensitized. Skin 
prick test reveals approximately 30 percent of the population are sensitized in this way with 
positive responses towards allergens, for instance house dust mites. Nevertheless, not all this  
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responders response clinically to house dust mites with hay fever, although nonresponders do 
have a 50 percent chance of developing hay fever in the future. 
1.3.2 Early Phase Response 
Allergic rhinitis manifest as recurrent bouts of sneezing, rhinorrhoea and nasal itchiness. 
Mediators such as histamine, leukotriene C4 and prostaglandin D2 are responsible for the 
production of symptoms in allergic rhinitis (Passali, D., 1999, Pawankar et al., 2009). These 
mediators released from the mast cells after it degranulates once their cell bound – IgE has 
been cross linked by allergen. Some of them are preformed in the mast cells cytoplasmic 
granules, others like leukotriene and prostaglandins are formed from cell membrane 
arachidonic acid which then undergo metabolic pathways to prostaglandins(via 
cyclooxygenase pathway) and leukotrienes (via lipooxygenase pathway) (Sampson,A.P.1996) 
Histamine will increase ipsilateral glandular secretion by its action on mucus cells and 
vessels, while secretion on the contralateral side mediated through neural reflexes 
(Wagenmann et al., 1997).Its action on sensory nerves will induces itching and sneezing 
(Quah et al., 1997). Histamine mainly causes rhinorrhoea, sneezing and itchiness with less 
marked effect on nasal obstruction.Its effect on nasal obstruction requires relatively high 
concentrations. The response is of short duration. Its action on endothelial cells and blood 
vessels result in vasodilatation, plasma exudation and edema (Proud et al., 1983, Pullers et 
al., 1999 and Ricca V et al., 1986). 
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Histamine also possesses proinflammatory and immunomodulatory properties (Noval 
et al.,1997).These includes upregulation of adhesion molecules on vascular endothelial cells, 
increased production of cytokine IL-6 and IL-8 by endothelial cells and activation of 
epithelial cells with consequent ICAM 1 expression and cytokine production. 
            Prostaglandin D2 release will cause sustained nasal obstruction and it is ten times 
more potent than histamine (Howarth et al., 1997).Prostaglandin D2 is predominantly 
released following mast cell degranulation. Leukotriene will increase vascular permeability 
and oedema and is involved in eosinophil recruitment (Sampson et al, 1984, James, 2002). 
Leukotrienes belong to the family of eicosanoids. It is generated by the lipooxygenase 
pathway. The suphidopeptide or cysteinyl leukotrienes previously known as slow reacting 
substance of anaphylaxis (SRS-A).It plays an important role in asthma and rhinitis. 
Leukotriene B4 induces neutrophil recruitment (Szucs et al., 2002). 
The other cytokines that were released following mast cells degranulation are TH2 
cytokines such as IL-4, IL-5, IL-3 and pro-inflammatory cytokines such as IL-6, IL-8, IL-10 
and TNF-alpha (Johnson, D.A., Hricik J.G., 1993). Th2 cytokines release following mast 
cells degranulation which is important in regulation of IgE response (Okuda M et al., 1997) 
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1.3.3 Late phase response 
During late phase response it is more inflammatory in nature and involves ingress of 
eosinophil, mast cells, T lymphocytes and macrophages into local reaction site (Bascom et 
al., 1988).the symptoms that were produced during this phase are mainly nasal obstruction 
and hyperactivity. A late phase response may progress in up to half of the individual tested 
especially if high doses of allergen are used (Arbes et al., 2005). 
Eosinophils first described by Ehrlich in 1879, are associated with asthma, skin and 
parasitic diseases. They represent less than 1% of the circulating cells in the peripheral blood. 
The eosinophils migrates into the tissue upon appropriate signal by mechanism which 
involves chemokines, cytokines, and adhesion molecules. Granulocyte macrophage colony-
stimulating factor (GMCSF) and IL-5 enhance eosinophil recruitment, terminal maturation 
and expression of their adhesion molecules. Exotoxin and chemokines for instance regulated 
on activation, normal T expressed and secreted (RANTES) also act on eosinophil recruitment 
and possibly activation. Once the eosinophil enter the tissue, eosinophil gets mature and 
remain alive for days and weeks, depending on survival signals from their local environment 
mature eosinophils, which can be found in nasal mucosa and secretions containing eosinophil 
cationic protein(ECP), eosinophil – derived neurotoxin (EDN), major basic protein (MBP), 
eosinophil peroxidase and beta glucuronidase (Szucs et al.,2002). 
Eosinophils are able to synthesize and release cytokines, for instance IL-3,IL-
5,GMCSF, proinflammatory cytokines and as well as chemokines, transforming growth 
factor (TGF) beta-1,reactive oxygen intermediate, lipid mediators, thromboxane B2 and 
prostaglandin E1 (Szucs et al.,2002). 
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An increased T lymphocytes (CD 4+ and CD 25 + ) are also found in the epithelium 
and submucosa of the individuals with allergic rhinitis (Varney et al., 1992). Increased 
expression of IL-4, IL-5, GMCSF at mRNA level was noted. In perennial rhinitis, there was 
an increase in CD4 + T cells and B cells in the nasal mucosa, again with a Th2 cytokine 
pattern (Varga et al., 1999). Besides, macrophages also were found to be increased in nasal 
mucosa in both seasonal and perennial rhinitis (Holm et al., 1995). 
In patients with asthma and rhinitis, epithelial cells are activated and they result in 
increased production of adhesion molecules, inflammatory mediators such as IL-6, IL-8 and 
GMCSF (Canonica et al., 1995). Epithelial cells are more sensitive to air pollutants for 
instance diesel exhaust particles in allergic as compared to normal individuals (Devalia et al., 
1999). 
              1.3.4 Systemic activation 
Allergic rhinitis is well known as localized allergic reaction. However, there is 
evidence in the literature that production of eosinophil and basophil precursors from bone 
marrow do happen following exposure of nasal mucosa and lung to allergen. These precursor 
cells will adhere to the reaction site mediated by selectins and adhesion molecules where they 
infiltrate and mature (Denburg et al., 1999). 
Allergic responses as described above can happen via non IgE mediated mechanisms. 
Some allergen, for instance house dust mites are able to elicit those response through their 
enzymatic proteolytic activity which activates the cells directly. They can also induce 
chemokines and cytokines release from epithelial cells and induce airway inflammation  
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without medication by IgE. Mast cells degranulation can occur due to certain drugs for 
instance aspirin, morphine and codeine which act directly on mast cells (Roche et al., 1997) 
 
 
 
Fig. 1: Pathophysiology of Allergic Rhinitis (Source: Encyclopedia Britannica,Inc 1994)  
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1.4    Classification of Allergic Rhinitis 
 
Recently WHO has classified allergic rhinitis, entitled as “Allergic Rhinitis and its 
Impact on Asthma” (ARIA), as in part, modified this classification. The old terms of 
perennial and seasonal allergic rhinitis is replaced by intermittent and persistent based on 
symptoms duration (Demoly et al., 1998, Bauchau V et al., 2004). According to the 
document, the patients who are symptomatic less than 4 days a week or less than 4 weeks is 
termed as Intermittent Allergic Rhinitis (IAR). Symptoms more than 4 days a week or more 
than 4 weeks is termed as Persistent allergic rhinitis (PAR).  
The ARIA classification also introduced a system for assessing allergic rhinitis 
severity on the presence or absence of impairment in any 4 health related quality of life 
namely, sleep, daily activities, work/school, and troublesome symptoms. According to ARIA 
workshop group, allergic rhinitis was defined as mild when there was no impairment in 1 or 
more areas. Classification of AR-based on duration (Adapted from ARIA, Allergic rhinitis 
and its impact on Asthma Workshop report, Allergy, 2002) 
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Table1: Classification of Allergic Rhinitis based on duration of symptoms 
 
Intermittent Allergic Rhinitis (IAR) 
 
Persistent Allergic Rhinitis(PAR) 
 
< 4 days per week    OR 
< 4 weeks per year 
 
 
>4 days per week and 
>4 weeks per year 
 
 
 
1.5    Diagnosis  
 
The diagnosis of IgE mediated allergic diseases is routinely based on 4 types of 
evidence. Three types are part of the clinical work up for allergy, which involves a detailed 
patient history and physical examination, skin testing, and in certain cases, challenge testing 
with a suspected allergen. The fourth type is a laboratory procedure, most commonly in vitro 
determination of circulating serum IgE antibodies specific for allergens. 
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1.5.1  Skin Prick Test 
 
  Fig.2 : Skin prick test ( Source:GLORIA,Module 1 ,World Allergy Association,2011) 
 
Fig.3: Positive skin prick test (Source: GLORIA, Module 1, World Allergy 
Association, 2011) 
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It is considered as the conventional way to test for the presence of allergen-specific 
IgE and to detect IgE bound to the surface of mast cells in the skin. Allergen in solution is 
applied to the skin, generally the volar surface of the forearm. When the skin is pricked with 
a lancet the allergen comes into contact with specific IgE, bound to the surface of cutaneous 
mast cells. The binding of the allergen leads to activation and the immediate release of 
mediators including histamine. The release of mediators’ results in a wheal and flare type 
reaction and the test is generally reported as the maximal wheal diameter after 15-20 minutes. 
The test is considered as positive if the size or diameter of wheal is 3 mm or more. These 
tests are simple, quick and the most sensitive method of detecting specific IgE. Skin prick 
tests are particularly helpful in excluding potential allergens as a cause of symptoms as false 
negatives are uncommon. 
 
1.5.2   Serum specific IgE 
In this study we are using ImmunoCAP 100 as the diagnostic method to measure 
allergen serum specific IgE. The ImmunoCAP 100 is designed as a sandwich immunoassay, 
has an extremely high total binding capacity, provides high sensitivity and very low 
concentrations of IgE antibodies can be detected. ImmunoCAP has an extremely high total 
binding capacity, achieved through a high binding capacity per mg cellulose in combination 
with an optimal amount of cellulose in each solid phase. This ensures binding of all relevant 
antibodies, regardless of antibody affinity, still giving low non-specific binding 
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1.6 Management of allergic rhinitis 
Management of allergic rhinitis includes patient education and counselling, 
medications and allergen specific immunotherapy. Surgery only reserved in selected patients.  
(Bousquet et al., 2001). Environmental control is more controversial (Schmidt et al., 2005). 
Medications for allergic rhinitis can be given intranasally or orally .The ARIA guidelines 
recommend that treatment be prescribed according to severity and duration of disease 
(Bousquet et al., 2001). 
 
1.6.1 Antihistamines 
Antihistamines help to reduce symptoms of running nose, itching, and sneezing and 
have little or no effect on nasal obstruction (Campbell A et al., 1992) although there are 
recent expectation e.g. desloratidine and levocetrizine (Horak et al., 2002). Chlorpheniramine 
is a first generation antihistamine, if possible need to be avoided as this group of 
antihistamine has effects of sedation, psychomotor retardation and mental impairment. This is 
probably due to its capability of crossing blood brain barrier (Timmerman et al., 1992). 
Antihistamine seems to be effective given regularly rather than intermittently and can reduce 
allergic progression in pediatric age group (Ciprandi et al., 1997) . 
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1.6.2 Topical Glucocorticoids 
These medications are the most effective medicine, provided start earlier before 
allergen exposure for treatment of rhinitis (Weiner et al., 1998). Topical glucocorticoid helps 
to reduce inflammation and consequent hyperactivity, improves sense of smell, and reduce 
nasal and eye symptoms. The onset of action is slow and some improvement can be seen after         
6-12hours, with maximum effects after several days. Steroid bioavailability is lowest with 
fluticasone and mometasone, but in terms of efficacy there is no difference between various 
preparations (Scadding et al., 2002). Topical corticosteroid helps to reduce the relative risks 
of exacerbation of asthma by 50 percent or more if is combined with antihistamine (Adam et 
al., 2002 and Crystal et al., 2002). 
1.6.3 Sodium Cromoglycate 
This sodium cromoglycate spray is used three to four times daily. It is weakly 
effective against all rhinitis symptoms. This spray is useful for small children less than four 
years old for whom topical corticosteroid is not available (Engstrom et al., 1971) 
1.6.4 Nasal decongestants 
This medication are used topically and helps to lessens nasal obstruction, but causes 
rhinorrhoea. It is recommended for short term usage, and for instance prior to flying out in 
otitis media effusion and rhinosinusitis. Prolonged use might cause rhinitis medicamentosa ( 
Scadding et al.,1995).Systemic decongestants is not really effective and has more side effects 
for instance insomnia and hyperactivity in children, and hypertension in adults (Johnson et 
al.,1993 and Thomas et al.,1991) 
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1.6.5 Ipratropium Bromide 
This nasal spray is useful against watery rhinorrhoea and maybe curative if used 
regularly (Kaiser at al., 1995).Sometimes it is beneficial for allergic rhinitis patient who does 
not respond to corticosteroid alone (Dockhorn et al., 1999).This medication has side effects, 
for instance dry mouth and eyes and worsening of glaucoma and prostatism (Groth et al., 
1983). 
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1.7    Channa Striatus 
 
 
 
Fig. 4: Channa Striatus (Source: Online Journal of Animal and Feed Research Volume 
2: Issue 2, 2012) 
 
 
In a study by Somchit et al, (2008), it is reported that all three channa spp fish possess 
anti-inflammatory properties. The nutritive quality of three channa spp fish is a source of 
protein and fatty acid was investigated. All three species were rich in amino acid. All three 
channa spp fish contained archidonic acid which is a precursor for prostaglandin and 
thromboxane synthesis. This will interfere with the blood clotting process and its attachment 
to endothelial cells during wound healing (Mohsin, 1983). The levels of DHA in the fish 
would explain the use of Channa spp especially channa striatus for decreasing inflammation 
process (Mat Jais et al., 1998). Therefore, this fish have been suggested as a key component 
for healthy diets in humans. 
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Furthermore it is mentioned that channa striatus has potent anti-inflammatory and 
analgesic effects (Zakaria et al, 2005). Thus, we believe that channa striatus can strongly 
decrease the anti-inflammatory agents responsible for allergic rhinitis manifestations. In 
allergic rhinitis besides confirmation with positive relevant history, serum specific IgE to 
detect specific allergens are the standard method of investigation today (Quah et al., 1997). 
Positive serum specific IgE shows close association with nasal symptoms in response to 
allergen exposure in a general population. Channa striatus or referred as “Haruan” in Malay 
language, is usually consumed to promote healing in surgical wound but no study has been 
done on its anti-inflammatory effect in allergic rhinitis. There are no extensive studies on the 
benefit of channa striatus biomedical properties which can helps in the treatment of allergic 
rhinitis such as  reduce inflammatory process in manifestation of their symptoms and  
improve the quality of life. So, this study was proposed to evaluate the potential effect of 
channa striatus as an adjunct to treatment in allergic rhinitis patient. Channa striatus extract 
would be one of the alternative therapy used as combination with the proper treatment 
modalities. This study will offer new insight, generated new ideas of using our own natural 
remedies as one of the alternatives therapy in allergic rhinitis and can promote channa 
striatus product. Thus, it will help the agricultural sector to develop and increase our 
economic activities to a higher level in the future. 
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CHAPTER 2 
OBJECTIVES OF STUDY 
 
2.1  General Objective  
 
1. To determine the therapeutic effect of channa striatus in  allergic rhinitis patient 
  
2.2  Specific Objective 
 
1. To compare the total nasal symptom score between channa striatus  and placebo 
group 
2. To compare the levels of specific IgE between channa striatus and placebo group 
  
       2.3  Research hypothesis 
There is difference in terms of using channa striatus as therapeutic treatment in 
improving patients total nasal symptom score, and reduction in IgE levels 
 
2.4        Null hypothesis 
                There is no difference in outcome in giving channa striatus as a therapeutic         
                treatment of allergic rhinitis 
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CHAPTER 3 
METHODOLOGY 
 
Study design        : Prospective, randomized, double blinded, comparative clinical trial  
Study setting : Otorhinolaryngology – Head & Neck Surgery (ORL-HNS), general 
outpatient clinic, Hospital Universiti Sains Malaysia (HUSM) 
Study population : Patients with allergic rhinitis 
Time Frame         : January 2013 until February 2014 
                           
Inclusion criteria: 
-Patients age between 18-50 years old  
-Allergic rhinitis diagnosis based on total nasal symptom score, nasoendoscopy 
findings, and a positive skin prick test 
 
Exclusion criteria: 
-Patients with concurrent rhinosinusitis or other nasal pathology 
-Patients with disabling co-morbid condition such as severe hematologic disorders, 
renal disease, liver disease, neoplasms 
-Pregnancy or nursing mothers 
-Patients with history of allergy to ikan haruan (channa striatus) or ikan haruan  
product 
-Patients who has undergone surgical intervention for factors contributing to allergic 
rhinitis 
-Patients on any form of traditional medication 
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3.1  Sample size determination 
 
Sample size calculation was formulated using PS software. 
Sample size based on previous literature by Yang et al, 2010, comparing usage of traditional 
chinese medicine, Xin-yi-san, reducing nasal symptoms of patients with allergic rhinitis by its 
diverse immunomodulatory effects. 
Using PS software:- 
α= 0.05 
Power=0.8 
σ = 16 
δ  = 10 
n=32 per arm 
2n= 64 
Expected 10% drop-out;  
  Sample size  = 64 x 1.1 
= 70 
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3.2   Details of Methodology 
 
1. This study was approved by ethics committee.  
2. Written consent were obtained from selected patients.  
3. Consented patients were randomized into the treatment and placebo groups. 
4. Treatment group patients received oral channa striatus extract (500mg). Placebo 
group patients received corn starch (200mg). 
5. Both groups of patients continued their nasal spray and loratidine. 
6. Subject eligibility were determined before treatment randomization. Subject 
numbers were allocated strictly sequentially, as subjects are eligible for 
randomization. Investigators were blinded in the randomization.  
7. A randomization list generated using computer provided allocation of subject 
numbers in a ratio of 1:1 to treatment and placebo group.   
8. This is double blind study and once a subject has been randomized, the study 
treatment that they will receive will not be known to the subject and the 
investigator.  
9. Patients with symptoms of allergic rhinitis were screened with detailed history, 
physical examination and nasoendoscopy. 
10. Patients with positive symptom score, positive nasoendoscopy findings and 
positive skin prick test was recruited in this study. 
11. Baseline blood investigation such as full blood count (FBC), Renal profile (RP), 
Liver function test (LFT) and Immunoglobulin E (IgE) levels were taken prior 
commencement of treatment.                                                                   
